Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproic acid and lenalidomide in MDS with favorable risk
NCT00977132Phase 2Terminated
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Oct 2009
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valproic acid, lenalidomide in myelodysplastic syndrome (MDS), sponsored by Heinrich Heine University Düsseldorf. Started Oct 2009; status: terminated.
02
Drugs
valproic acidlenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00977132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00977132.